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A b s t r a c t
Introduction: The impact of an infection that requires antibiotic treatment (IRAT) after an acute ischemic stroke (AIS) treated 
with mechanical thrombectomy (MT) remains unclear. 
Aim: Here, we studied the prevalence and the profile of IRAT in patients with AIS treated with MT, aiming to identify predictive 
factors and prognostic implications at 90 days after stroke. 
Material and methods: We analyzed parameters available within 24 h after AIS including demographics, risk factors, National 
Institutes of Health Stroke Scale (NIHSS) upon admission and 24 h later, hemorrhagic transformation (HT) on computed tomogra-
phy, and several clinical and biochemical markers. The outcome measures were the modified Rankin Scale (mRS) 0-2 and 90 days 
post-stroke mortality.
Results: We included 291 patients; in 184 (63.2%) patients MT was preceded by intravenous thrombolysis (IVT), and 83 (28.5%) 
patients developed IRAT. Multivariate analysis showed that male sex and hemorrhagic transformation on CT taken 24 h after stroke in-
creased the risk of IRAT. We found that younger age, male sex, lower delta NIHSS, shorter time from stroke onset to groin puncture, better 
recanalization and a lack of hemorrhagic transformation on CT taken 24 h after stroke favorably affected outcome at day 90. Multivariate 
analysis showed that older age, higher delta NIHSS, unknown stroke etiology and lack of treatment with IVT were independent predictors 
of death up to day 90. Infection that required antibiotic treatment did not enter in the models for the studied outcome measures.
Conclusions: In AIS patients treated with MT, IRAT is not an independent factor that affects favorable outcome or mortality 
90 days after stroke.
Key words: mortality, acute ischemic stroke, infections, antibiotic therapy, mechanical thrombectomy, long-term outcome.
S u m m a r y
To the best of our knowledge, no study has yet evaluated the prevalence and the profile of infection that requires antibi-
otic treatment (IRAT) or parameters affecting the risk of IRAT and its prognostic significance in patients with acute ischemic 
stroke (AIS) treated with mechanical thrombectomy (MT). We included 291 AIS patients and 83 (28.5%) developed IRAT. We 
found that IRAT was not an independent factor affecting favorable outcome or mortality 90 days after stroke; however, we 
confirmed the prognostic significance of commonly accepted parameters such as age, sex, neurological deficit assessed 
by NIHSS score, time from stroke onset to groin puncture, recanalization rate as measured by the Thrombolysis in Cerebral 
Infarction (TICI) score, and hemorrhagic transformation of ischemic lesion on CT after the procedure.
Introduction
Ischemic stroke is an important cause of morbidity 
and mortality worldwide with a considerable social and 
economic burden [1]. Since 2015, mechanical thrombec-
tomy (MT) has been an approved treatment option for 
acute ischemic stroke (AIS) patients with their acute clot 
located in a large brain artery and who do not respond to 
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intravenous thrombolysis (IVT) or who are outside their 
therapeutic window for IVT or for whom IVT is contrain-
dicated [2]. MT markedly improves functional outcome of 
AIS compared to other treatment options [3]. Time from 
stroke onset to groin puncture is an important modifiable 
parameter affecting prognosis of patients treated with 
MT [4]. The question arises whether the efficacy of MT 
can be improved even more by identifying other modifi-
able factors that affect outcome. 
Infection that requires antibiotic treatment (IRAT) is 
a common medical complication in AIS patients [5]. Sev-
eral parameters that increase the risk of infection in AIS 
patients have been identified including age, sex, several 
comorbidities, cognitive alterations, preadmission de-
pendency, speech problems, dysphagia, stroke severity, 
etc. [6–11]. Infection in AIS correlates significantly with 
longer in-hospital stay, higher medical costs [12, 13], and 
poor prognosis and mortality [14, 15]. 
To the best of our knowledge, no study has yet evalu-
ated the prevalence and the profile of IRAT or parameters 
affecting the risk of IRAT and its prognostic significance 
in patients treated with MT. Knowledge about this im-
portant clinical aspect of AIS would be helpful in estab-
lishing standards of prevention.
Aim 
We evaluated the prevalence and the profile of IRAT 
in AIS patients treated with MT. We also studied wheth-
er IRAT affected long-term favorable outcome defined by 
the modified Rankin Scale (mRS) score from 0 to 2 or 
mortality at day 90.
Material and methods
We retrospectively analyzed data prospectively col-
lected from 291 patients with AIS who underwent MT at 
the Comprehensive Stroke Center in Krakow in the peri-
od from January 2013 to August 2019. The study was ap-
proved by the Jagiellonian University Ethical Committee 
(KBET 54/B/2007). We received written informed consent 
from all participants. All procedures were performed in 
accordance with the Declaration of Helsinki [16]. Stroke 
diagnosis was consistent with the WHO definition [17]. 
Details of patients’ check-ups have been described pre-
viously [4].
In the present study we examined the following 
parameters: (1) demographics including age and sex; 
(2) stroke risk factors including hypertension, diabetes 
mellitus, ischemic heart disease, atrial fibrillation (AF), 
smoking status (smokers were those who were smok-
ing while they were recruited into the study or those 
who had smoked in the past); (3) clinical data such as 
the TICI scale after the procedure [18], time-lapse from 
stroke onset to groin puncture (SO-GP), and stroke se-
verity on admission and 24 h later according to the Na-
tional Institutes of Health Stroke Scale (NIHSS) [19]. Del-
ta NIHSS was defined as the difference between NIHSS 
score tested 24 h after MT and upon hospital admission; 
low scores reflect improvement, and high scores indi-
cate deterioration. We also measured post-treatment 
hemorrhagic transformation on computed tomography 
(CT) taken 24 h after stroke (patients were categorized 
as with or without bleeding), body temperature on ad-
mission, and stroke etiology according to the Trial of 
Org10172 in Acute Stroke Treatment (TOAST) criteria 
[20]. For this project the participants were classified as 
those with unknown etiology and those with a defined 
etiology (large vessel disease stroke, small vessel dis-
ease stroke, cardio-embolic stroke or stroke due to rare 
etiology).
We studied the occurrence of infection that required 
antibiotic treatment during hospitalization (IRAT). Diag-
nosis of infection was based on clinical symptoms, e.g., 
fever, laboratory tests, microbiological assays, and chest 
X-rays. We considered the following types of infection: 
pneumonia, urinary tract infection, thrombophlebitis, 
and wound infection. We distinguished two types of 
pneumonia: community acquired pneumonia (CAP) and 
nosocomial pneumonia. Routinely in our hospital, first 
line treatment for patients with CAP is ceftriaxone and 
for patients with nosocomial pneumonia is ceftriaxone 
and levofloxacin. If these antibiotics are not effective we 
modify the treatment according to the antibiogram. For 
patients with urinary tract infection the first-line treat-
ment is cefuroxime. If this antibiotic is not effective we 
modify the treatment according to the antibiogram. Fast-
ing blood samples on the first morning after admission 
were also tested for white blood cell count (WBC), hemo-
globin levels, glucose levels, creatinine, TSH, low-densi-
ty lipoprotein (LDL), high-density lipoprotein (HDL), and 
triglycerides. We also studied treatment with IVT prior to 
MT and the following treatments before AIS: antiplate-
lets, anticoagulants, and statins. 
The outcome measures were the modified Rankin 
Scale [21] (mRS) 0-2 and mortality 90 days after stroke. 
Statistical analysis 
Clinical characteristics and outcomes between the 
groups were compared using unpaired Student’s t-test 
or the c2 test where appropriate. To identify potential in-
dependent predictors of outcome, variables with p-val-
ues < 0.05 in the univariate regression analyses for IRAT, 
favorable outcome or death were subsequently included 
in multivariate regression analyses. 
All statistical calculations were performed by Statisti-
ca software version 12.5 (TIBCO software INC). P-values 
below 0.05 were considered statistically significant. 
Results
MT was performed in 291 patients. Infection that 
required antibiotics during hospitalization was seen in 
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83 (28.5%) patients: 51 (17.5%) patients developed 
pneumonia, 28 (9.6%) developed urinary tract infections, 
1 (0.3%) patient developed wound infection, 1 (0.3%) pa-
tient developed sepsis, and 2 (0.7%) patients developed 
an infection of unclear origin. Eleven (21.6%) patients 
developed CAP, and 40 (78.4%) developed nosocomial 
pulmonary infection. Ten (19.6%) patients required an 
antibiogram, since they did not respond to first-line an-
tibiotics. The cultures revealed the following pathogens: 
Staphylococcus aureus MSSA (3); Staphylococcus aureus 
MRSA (2); Klebsiella pneumoniae ESBL (+) (2); Klebsiella 
pneumoniae (1); Escherichia coli (1); Enterobacter cloacae 
(1). In each case antibiotics were used according to the 
antibiogram. Nineteen out of 28 patients with urinary 
tract infection (67, 9%) responded to the first-line anti-
biotic. In the remaining 9 patients the cultures revealed 
the following pathogens: Escherichia coli (5); Escherichia 
coli ESBL (+) (1); Proteus mirabilis (1); Enterococcus fae-
calis (1); Staphylococcus aureus MSSA (1). In each case 
antibiotics were used according to the antibiogram. The 
blood culture of the patient with sepsis revealed Staph-
ylococcus aureus and the patient was treated according 
to the antibiogram. Cultures from urine, blood and from 
bronchoalveolar lavage from the 2 patients with infection 
of unclear origin did not show any pathogens. Patients 
were treated with ceftriaxone and levofloxacin. 
Patients who developed IRAT were older and more 
often were men. Univariate analysis showed that sever-
al features correlated with IRAT: diabetes mellitus, isch-
emic heart disease, AF, higher delta NIHSS, hemorrhagic 
transformation on CT taken 24 h after stroke, antiplatelet 
treatment, statin use before stroke, and higher glucose 
levels on the next day after admission (Table I). Multi-
variate analysis showed that male sex and hemorrhagic 
transformation on CT taken 24 h after stroke increase the 
risk of IRAT (Table II). 
Here, 154 (52.9%) patients had favorable outcomes 
at day 90. Univariate analysis showed that patients with 
a  favorable outcome were significantly younger, more 
often male, and with lower rates of diabetes mellitus. 
They had a significantly better recanalization rate, short-
er time from stroke onset to groin puncture, and lower 
delta NIHSS than those with a  poor outcome. Patients 
with favorable outcomes were less likely to have a hem-
orrhagic transformation on CT, more likely to be treated 
with IVT and less likely to develop IRAT. They also had 
higher hemoglobin levels and lower glucose levels the 
next morning (Table I). 
Multivariate analysis showed that younger age, male 
sex, lower delta NIHSS, better recanalization as graded 
by the TICI score, shorter time from stroke onset to groin 
puncture, and lack of hemorrhagic transformation on CT 
taken 24 h after stroke favorably affected outcomes at 
day 90. Infection that required antibiotic treatment did 
not affect this outcome (Table II). 
There were 63 (21.6%) deaths within 90 days. Pa-
tients who died more often were diagnosed with stroke 
of unknown origin while those who survived more often 
had a diagnosis of large vessel disease stroke (Table I). 
Univariate analysis showed that patients who died were 
older. Compared to their surviving counterparts, patients 
who died had worse recanalization as graded by TICI 
score, higher delta NIHSS, more frequently presented 
with hemorrhagic transformation on CT taken within 24 h 
after treatment and more often had stroke of unknown 
etiology. They less frequently had intravenous thrombol-
ysis and they more often used statins before stroke and 
were more likely to develop IRAT. They had lower hemo-
globin levels, higher WBC counts, and higher glucose lev-
els the next morning after admission. Multivariate analy-
sis showed that older age, higher delta NIHSS, unknown 
stroke etiology and lack of treatment with IVT were inde-
pendent predictors of death up to day 90.
Discussion
Many studies in patients with AIS, irrespectively of 
their acute treatment method [14, 15, 22–24], focus on 
analyzing the prevalence, the profile, and the prognostic 
significance of infection. Infection in AIS is an important 
aspect of stroke clinics, i.e., with respect to complications, 
lengths of hospital stay, or prognosis; however, clinical 
trials have shown that preventive antibiotic therapy did 
not improve functional outcome in relatively unselected 
AIS patients [25, 26]. 
To the best of our knowledge, the clinical characteris-
tics of infection in AIS patients treated with MT have not 
yet been studied. MT is clearly better than other AIS ther-
apies with a number needed to treat (NNT) less than three 
for improved functional outcome [3]; thus, the prognosis 
in AIS treated with MT may be determined by a different 
set of factors relative to other subgroups of AIS patients. 
For comparison, the NNT in AIS patients treated with IVT 
within 90 min after stroke onset is 5; this value is nine for 
those treated 3.0 to 4.5 h after stroke [27]. 
The prevalence of infection in AIS is high, ranging 
from 5% to 65% depending on the study population and 
the definition of infection [28]. It was 28.5% in our study. 
The most common infection in AIS is pneumonia – a re-
cent systematic review reported a prevalence of 14.3% 
[29]. The prevalence of pneumonia is slightly higher in 
our study (17.5%).
From the pathophysiologic point of view the high 
risk of infection in AIS patients is thought to be related 
to stroke-induced immunodepression syndrome (SIDS), 
which is responsible for a  long-lasting alteration of the 
lymphocyte profile and disturbances in cytokine produc-
tion [30, 31]. Additionally, the key factor specifically in-
creasing the risk of pneumonia in AIS is dysphagia, caus-
ing oropharyngeal aspiration [32].
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Table II. Multivariate logistic regression models showing: (1) factors affecting risk of infection that requires 
antibiotic treatment, (2) factors affecting favorable outcome (mRS: 0–2) at day 90 and (3) factors affecting 
mortality (mRS: 6) at day 90
Factors affecting risk of infection that requires antibiotic treatment OR 95% CI P-value
Demographics:
Age [years] 1.02 0.995–1.05 0.1
Sex (female) 0.39 0.21–0.72 0.0026
Stroke risk factor:
Diabetes mellitus 1.01 0.52–1.97 0.97
Ischemic heart disease 1.47 0.79–2.74 0.22
Atrial fibrillation 1.42 0.76–2.63 0.27
Clinical parameters:
Delta NIHSS 1.02 0.99–1.05 0.18
Hemorrhagic transformation of ischemic lesion on CT 24 h after admission 1.84 1.05–3.25 0.034
Treatment:
Antiplatelet treatment before AIS 1.5 0.68–3.31 0.31
Statins before AIS 1.16 0.5–2.73 0.72
Biochemical parameters:
Fasting glucose level on the next day after admission 24 h [mmol/l] 1.12 0.98–1.27 0.094
Factors affecting favorable outcome at day 90 (mRS: 0–2) OR 95% CI P-value
Demographics:
Age [years] 0.95 0.93–0.98 0.00048
Sex (female) 0.46 0.23–0.93 0.031
Stroke risk factors:
Diabetes mellitus 0.60 0.28–1.29 0.19
Clinical parameters:
Delta NIHSS 0.87 0.82–0.91 0.00000022
Post-thrombectomy TICI score: 0, 1, 2a 0.27 0.12–0.58 0.00086
Time from stroke onset to groin puncture [h] 0.78 0.64–0.97 0.02
Infection that requires antibiotic treatment 0.72 0.34–1.49 0.37
Hemorrhagic transformation of ischemic lesion on CT 24 h after admission 0.47 0.24–0.9 0.023
Treatment:
Intravenous thrombolysis 1.33 0.68–2.62 0.4
Biochemical parameters:
Fasting glucose level on the next day after admission 24 h [mmol/l] 0.93 0.8–1.09 0.39
Hemoglobin [g/dl] 1.14 0.97–1.34 0.11
Factors affecting risk of death at day 90 OR 95% CI P-value
Demographics:
Age [years] 1.04 1.009–1.07 0.010
Sex (female) 0.65 0.30–1.42 0.27
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The most commonly mentioned predictors of infection 
in AIS patients, irrespectively of their acute treatment sta-
tus, are older age, sex for different type of infection, stroke 
severity, bedridden state, dysphagia or reduced bulbar 
reflexes, chronic obstructive pulmonary disease, diabe-
tes mellitus, or specific invasive maneuvers (feeding tube 
placement, urinary catherization, etc.) [6, 7, 24]. The pro-
file of factors affecting the risk of pneumonia in an unse-
lected group of AIS patients or patients treated solely with 
IVT is similar to those mentioned above [8–11, 22, 23].
Many previous studies in AIS patients regardless of 
their acute treatment status showed that infection leads 
to worse outcomes. The occurrence of any post-stroke in-
fection is associated with the odds ratio for a poor func-
tional outcome that varied from 0.9 to 4.4; the odds ratio 
for mortality varies from 1.5 to 6.0. Regarding pneumo-
nia, the evidence for functional outcomes is limited, and 
the odds ratio varies from 1.7 to 52. For mortality, the 
odds ratio varies from 2.1 to 3.0 [28]. 
In the present study univariate analysis confirmed 
that infection was less frequent in patients with better 
prognosis and significantly more common in those who 
died. Interestingly, infection did not enter the logistic re-
gression models for either prognostic outcome (favorable 
outcome or death at day 90). In our study, however, we 
confirmed the prognostic significance of several factors 
previously shown to be related to long-term prognosis in 
patients treated with MT, such as age [33], sex [34], time 
from stroke onset to groin puncture [35], recanalization 
after MT [33, 36], and hemorrhagic transformation on CT 
after the procedure [33]. We also observed for the first 
time that lower delta NIHSS – which in our study reflects 
the neurological improvement after the procedure – was 
an independent factor affecting favorable outcome at 
day 90. A higher delta NIHSS reflects clinical deteriora-
tion after the procedure in our study, and this score was 
an independent risk factor of death at day 90. Our find-
ings showing the correlation of AIS etiology and the lack 
of IVT treatment before MT with 90 day mortality needs 
confirmation in different populations. 
Our study has some limitations. First, this was a retro-
spective and single-center study including only patients 
who could give signed consent. This study was based on 
data acquired in a single hospital, and thus the results 
may be not comparable with patients collected in a mul-
ticenter prospective study. Further prospective studies 
are needed to validate our findings. Unfortunately, we 
did not collect C reactive protein levels from the first 
67 cases included in our study; thus, this parameter was 
not included in the present analysis. We are aware that 
this is an important factor affecting stroke outcome [37]. 
Finally, we did not systematically collect information 
about dysphagia or intubation during the procedure; both 
are important factors related to the risk of pneumonia.
Conclusions 
In the present study infections are a common finding 
in patients with AIS treated with MT, and in contrast to 
studies on unselected AIS patients or patients treated 
with IVT, the presence of IRAT did not affect the studied 
long-term outcome measures. 
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Factors affecting risk of death at day 90 OR 95% CI P-value
Clinical parameters:
Post-thrombectomy TICI score: 0, 1, 2a 1.18 0.30–1.42 0.68
Delta NIHSS 1.17 1.10–1.24 0.00000019
Hemorrhagic transformation on CT 24 h after admission 2.00 0.96–4.20 0.062
Infection that requires antibiotic treatment 1.21 0.56–2.63 0.63
Stroke etiology:
Unknown etiology of stroke 3.55 1.55–8.15 0.0027
Treatment:
Intravenous thrombolysis 0.41 0.19–0.88 0.0021
Biochemical parameters:
WBC count [μl] 1.10 0.99–1.23 0.065
Fasting glucose level on the next day after admission 24 h [mmol/l] 1.05 0.96–1.15 0.31
AIS – acute ischemic stroke, CI – confidence interval, CT – computed tomography, mRS – modified Rankin Scale, NIHSS – National Institutes of Health Stroke Scale, 
OR – odds ratio, TICI – Thrombolysis in Cerebral Infarction, WBC – white blood cells.
Table II. Cont.
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